Dr. Martens rallies on cost-cutting plan and US reboot hopes
Investors in Dr. Martens (DOCS) have endured a torrid time since the iconic footwear firm's 2021 IPO (initial public offering), with the shares booted around 80% lower following a slew of profit warnings.
Results for the year ended 31 March 2024 revealed another drop in profits after a challenging year, mostly driven by issues in the US, the FTSE 250 company's largest market, where it has encou...